Houston health tech innovator collaborates on promising medical device funded by DOD

team work

Yaxin Wang is director of THI's Innovative Device & Engineering Applications Lab. Photo via texasheart.org

The United States Department of Defense has awarded a grant that will allow the Texas Heart Institute and Rice University to continue to break ground on a novel left ventricular assist device (LVAD) that could be an alternative to current devices that prevent heart transplantation and are a long-term option in end-stage heart failure.

The grant is part of the DOD’s Congressionally Directed Medical Research Programs (CDMRP). It was awarded to Georgia Institute of Technology, one of four collaborators on the project that will be designed and evaluated by the co-investigator Yaxin Wang. Wang is part of O.H. “Bud” Frazier’s team at Texas Heart Institute, where she is director of Innovative Device & Engineering Applications Lab. The other institution working on the new LVAD is North Carolina State University.

The project is funded by a four-year, $7.8 million grant. THI will use about $2.94 million of that to fund its part of the research. As Wang explained to us last year, an LVAD is a minimally invasive device that mechanically pumps a person’s own heart. Frazier claims to have performed more than 900 LVAD implantations, but the devices are far from perfect.

The team working on this new research seeks to minimize near-eventualities like blood clot formation, blood damage, and driveline complications such as infection and limitations in mobility. The four institutions will try to innovate with a device featuring new engineering designs, antithrombotic slippery hydrophilic coatings (SLIC), wireless power transfer systems, and magnetically levitated driving systems.

Wang and her team believe that the non-contact-bearing technology will help to decrease the risk of blood clotting and damage when implanting an LVAD. The IDEA Lab will test the efficacy and safety of the SLIC LVAD developed by the multi-institutional team with a lab-bench-based blood flow loop, but also in preclinical models.

“The Texas Heart Institute continues to be a leading center for innovation in mechanical circulatory support systems,” said Joseph G. Rogers, MD, the president and CEO of THI, in a press release.

“This award will further the development and testing of the SLIC LVAD, a device intended to provide an option for a vulnerable patient population and another tool in the armamentarium of the heart failure teams worldwide.”

If it works as hypothesized, the SLIC LVAD will improve upon current LVAD technology, which will boost quality of life for countless heart patients. But the innovation won’t stop there. Technologies that IDEA Lab is testing include wireless power transfer for medical devices and coatings to reduce blood clotting could find applications in many other technologies that could help patients live longer, healthier lives.

The study will include 10 hospitals enrolled as possible sites and is slated to begin in 2024. One location is Houston’s own Texas Heart Institute. Photo courtesy of BiVACOR

Houston medical device company with long-lasting artificial heart reaches FDA milestone

feasibility focused

A Houston company with a breakthrough heart health tech has received a green light from the FDA.

BiVACOR, a Houston-headquartered medical device company, has received FDA approval for its Total Artificial Heart (BTAH) IDE first-in-human early feasibility study (EFS). The BTAH device itself is designed to take over all function for patients with heart failure. The BTAH is roughly the size of a human fist, which means that, while it could support an active adult male, it may also fit many women and children.

Led by CEO Thomas Vassiliades, a former heart surgeon, BiVACOR is based on a system of magnetic levitation. “Our pump is just one moving impeller that sits in the middle of the housing where the blood is. Imagine an artificial heart — the container that has your blood — and the device spinning in the inside — basically a wheel spinning your blood to the rest of your body. The device is suspended by magnets — it's not touching anything,” Vassiliades told InnovationMap in a podcast earlier this year.

Because of that, BiVACOR could potentially last for a patient’s entire life with no wear — something, Vassiliades explains, is new to the field.

The EFS includes 10 hospitals enrolled as possible sites and is slated to begin in 2024. One location is Houston’s own Texas Heart Institute.

“I am eager to begin the BiVACOR Total Artificial Heart EFS to evaluate what I believe is a promising and potentially life-saving technology,” Joseph Rogers, CEO of the Texas Heart Institute, says in a press release. “The implantation of a TAH system is a potential treatment option for patients with heart failure who need support while on the heart transplant waiting list and for those who do not qualify for a transplant. The BTAH is designed to replace the function of the native heart completely. It is an impressive technology, and I am excited to see the potential of BTAH in treating patients with severe heart failure.”

BiVACOR’s chief medical officer is Texas Heart Institute cardiac surgeon William Cohn. He said that this EFS is a “critical milestone” for him and the BiVACOR team.

“This device will provide a unique approach to help patients currently with limited clinical options,” he explains.

The upcoming study is planned for biventricular heart failure patients who need a mechanical circulatory support device as a bridge to later transplantation. However, the team hopes that future studies will follow to chart the BTAH’s success with short-term and long-term destination therapy.

The Texas Heart Institute recently received its largest charitable donation in its history. Photo courtesy of THI

Massive $32M gift from former patient, new UH deal pump big changes into Houston organization

all heart

Leadership at The Texas Heart Institute has two major things to celebrate. First, it just received a $32 million donation from a patient — the largest charitable donation in its history.

Shortly after that news came out, the institute announced a new partnership with the University of Houston Tilman J. Fertitta Family College of Medicine that allows those UH medical students to join a clinical rotation at The Texas Heart Institute. The alliance means valuable insights and experience with both inpatient and outpatient cardiology for UH's future doctors.

"Students will have the chance to develop their skills in the diagnosis and management of cardiovascular conditions and will be taught by outstanding clinical educators,” said Dr. Joseph G. Rogers, president and CEO of The Texas Heart Institute and heart failure specialist at The Texas Heart Institute Center for Cardiovascular Care, in a press release announcing the news.

A game-changing gift that's all heart

As for that mammoth gift, the $32 million donation comes from Dr. Frederick M. Weissman, a neurologist from New York who was a patient at the Institute 40 years ago. Fittingly, huis gift will be used to support cardiovascular research.

This isn't Weissman's first gift to the institution. That came following his experience there in the mid-1980s, when he was treated by world-renowned cardiac surgeon Dr. Denton A. Cooley.

In November of 1986, Weissman wrote a check for $5,000; another followed the next month, with a note that read, in part, “my conscience compels me to make another contribution to The Texas Heart Institute. I don’t think I could ever repay you for what you and your staff have done for me.” Weissman and Cooley would go on to be friends throughout their lives.

When Dr. Weissman died in 2005, he left The Texas Heart Institute $500,000. The organization recently received the residual of his estate — valued at more than $32 million.

“Those of us who were fortunate enough to work with and be trained by Dr. Cooley know he was much more than just an incredibly gifted surgeon," renowned transplant surgeon and Co-director of THI’s Center for Preclinical Surgical & Interventional Research, Dr. O.H. “Bud” Frazier, said in press materials announcing the donation. "He established lifelong relationships with his patients and encouraged all of us to do the same. Dr. Weissman’s extraordinary generosity reflects the impact Dr. Cooley still has on the Institute he founded.”

A big leap for THI and the Coogs

Looking ahead, this game-changing gift and new affiliation with UH promises big things for students, doctors, researchers, and patients.

Medical students in rotation at The Texas Heart Institute will be exposed to progressive clinical care, allowing them to gain a deep understanding of the etiology, pathophysiology and management of cardiovascular disease from prevention to the most contemporary treatments available today. This level of hands-on experience is invaluable for future physicians, and will certainly contribute to the advancement of cardiovascular medicine.

"We are honored to launch this new affiliation with Fertitta Family College of Medicine,” said Dr. Jorge Escobar, director of undergraduate medical education at The Texas Heart Institute. "With new advances in diagnostic imaging, bedside testing, and clinical trials coupled with the complex care we provide to our patients, the rotation will be an impactful experience for the students."

Pumping with growth

Meanwhile, THI recently established The Texas Heart Institute Research Innovation Fund to propel the next generation of cardiovascular research by sparking discovery, supporting innovation, and recognizing excellence in high-risk, high-reward scientific exploration.

To that end, $5 million of the Weissman bequest has been designated to match philanthropic commitments of $10,000 or greater made to THI’s Research Innovation Fund and its priority initiatives in 2023, allowing donors the opportunity to double the impact of their research investment.

Founded in 1962, THI performed the first successful heart transplant and total artificial heart implant in the United States. It has gone on to become one of the world's leading institutions for cardiovascular treatment and research.

------

This article originally ran on CultureMap.

This week's roundup of Houston innovators includes Dr. Joseph Rogers of the Texas Heart Institute, Allie Danziger of Ampersand, Jeff Carlson of RioRaiz. Photos courtesy

3 Houston innovators to know this week

WHO'S WHO

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries — from SaaS to biotech — recently making headlines in Houston innovation.

Dr. Joseph Rogers, president and CEO of the Texas Heart Institute

Dr. Joseph Rogers has been at the helm of the Texas Heart Institute for around two years. He shares on the Houston Innovators Podcast about the innovative past, present, and future of THI. Photo via texasheart.org

Dr. Joseph Rogers, the president and CEO of the Texas Heart Institute, is passionate about preventative health care for THI and its patients, as he shares on the Houston Innovators Podcast. What's required is a comprehensive culture shift away from just using a pill to accomplish this goal.

Rogers says health care organizations are going to need to partner with other players — nonprofits, universities, local government — in ways never been done before. And THI is dedicated to this mission.

"Houston is the place to do this," he says. "The reason I think this is such an important community to address this problem is it's the most diverse city in the United States. And I've never lived anywhere or heard of another city that I was so convinced believed they could do anything they set their minds to. It's about making the community aware of the problem and a potential solution — and then working on trying to solve it."Read more.

Allie Danziger, senior vice president and general manager of student success at Ascent

Ampersand has been acquired by a college loan and student services provider based in San Diego. Photo ampersandpro.com

San Diego, California-based Ascent, a collegiate student loan company that also provides student support services, announced it has acquired Houston-based Ampersand, a software platform that provides skills training to young professionals.

With the acquisition, Allie Danziger, co-founder and CEO of Ampersand, joins Ascent as senior vice president and general manager of student success. She will lead the company's educational program that focuses on equipping students with skills from education to employment.

“Since launching Ampersand in 2020, we’ve received constant praise from employers, students, and universities on the real education-to-employment skills gap we are filling,” says Danziger in a news release. “I take immense pride in the fact that we’ve helped thousands of students enter the workforce with confidence, earn higher salaries, and get set on the right career path. I know joining the Ascent team will unlock even more opportunities for our combined companies, expanding our collective impact to millions of students and job seekers.” Read more.

Jeff Carlson, president and CEO of RioRaiz

With its blend of biotechnology, conservation, and education, RioRaiz seeks to inspire a new generation of conservationists. Photo via RioRaiz.org

Not only is Houston-based nonprofit RioRaiz looking to preserve biodiversity through biotechnology, the innovative organization also wants to offer transformative learning experiences to contribute to a healthier planet.

Led by Jeff Carlson, the president and CEO, RioRaiz's mission is driven by three core pillars: conservation, scientific discovery, and education.

"We have a list of priorities that is cataloged from input from our scientific collaborators, as well as our ability to deliver on our promises to our donors and supporters,” Carlson tells InnovationMap. Read more.

Houston health care leader drives innovation, preventive cardiovascular care

HOUSTON INNOVATORS PODCAST EPISODE 196

For 60 years, the Texas Heart Institute has been a part of Houston's innovation DNA. The organization's founder, Dr. Denton Cooley, performed first total artificial heart implantation in 1969 at THI. Now, decades later, the institutions third CEO continues to lead the innovation within cardiovascular care.

"Despite all of the advances, cardiovascular disease is still one of the largest killers of Americans. It actually kills more Americans than all types of cancer combined," Dr. Joseph Rogers, who was appointed president and CEO of THI in 2021, says on the Houston Innovators Podcast.

Rogers shares just a fraction of what the medical professionals are working on at THI on the show — from developing a drug that can improve the efficacy cell therapies, vaccines, and more to revolutionary stem cell treatments. Even with all this groundbreaking innovation in cardiovascular treatment, Rogers says one of the most crucial elements is prevention.

"The challenge of preventative medicine in general terms is there has been an under investment in terms of research," Rogers says. "I also think that many of us who live in developed countries have said, 'I think I can just take a pill to manage an underlying problem and I can continue to do whatever I'd like.'

"We use medicine as a crutch to allow us to continue living an opulent lifestyle," he continues.

THI is on a mission to evolve that way of thinking, Rogers says, but it's a comprehensive cultural shift that's needed.

"Medicine can control about 20 percent of this," Rogers says. "The rest is driven by the social drivers of health — early childhood experiences, food deserts, a lack of safe exercise facilities."

"We should act as a convener," Rogers says. "Houston is the place to do this.

"The reason I think this is such an important community to address this problem is it's the most diverse city in the United States. And I've never lived anywhere or heard of another city that I was so convinced believed they could do anything they set their minds to. It's about making the community aware of the problem and a potential solution — and then working on trying to solve it," he continues. "But I think all of the pieces are here to show the world how to do this at a community level."

Rogers shares more of his optimism about Houston as a heart health leader and innovator on the show. Listen to the interview below — or wherever you stream your podcasts — and subscribe for weekly episodes.

Ad Placement 300x100

Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Texas lands in top 10 states expected to be most financially affected by weather events

report

Texas — home to everything from tornadoes to hurricanes — cracks the top 10 of a new report ranking states based on impact from weather-related events.

SmartAsset's new report factored in a myriad of data from the Federal Emergency Management Agency to identify which states face the most financial risk due to various weather events. In the report, the states were ranked by the total expected annual financial losses per person. Texas ranked at No. 10.

"With a variety of environmental events affecting the wide stretch of the United States, each state is subject to its own risks," reads the report. "Particularly, tornadoes, wildfires, hurricanes, flooding, landslides, lightning and drought, among other events, can cause damage to buildings, agriculture and individuals alike. When considering insurance, residents and business owners in each state should account for historic and projected losses due to environmental events in their financial plans."

In Texas, the total expected annual loss per person is estimated as $283.15. The report broke down each weather event as follows:

Coastal flooding: $1.49
Drought: $3.48
Earthquake: $1.71
Heat wave: $8.16
Hurricane: $89.22
Riverine flooding: $66.05
Strong wind: $5.37
Tornado: $71.04
Wildfire: $8.26
Winter weather: $1.96

Louisiana ranked as No. 1 on the list with $555.55 per person. The state with the lowest expected loss per person from weather events was Ohio with only $63.89 estimated per person.

------

This article originally ran on EnergyCapital.

Exclusive: Houston hydrogen spinout names energy industry veteran as CEO

good as gold

Cleantech startup Gold H2, a spinout of Houston-based energy biotech company Cemvita, has named oil and gas industry veteran Prabhdeep Singh Sekhon as its CEO.

Sekhon previously held roles at companies such as NextEra Energy Resources and Hess. Most recently, he was a leader on NextEra’s strategy and business development team.

Gold H2 uses microbes to convert oil and gas in old, uneconomical wells into clean hydrogen. The approach to generating clean hydrogen is part of a multibillion-dollar market.

Gold H2 spun out of Cemvita last year with Moji Karimi, co-founder of Cemvita, leading the transition. Gold H2 spun out after successfully piloting its microbial hydrogen technology, producing hydrogen below 80 cents per kilogram.

The Gold H2 venture had been a business unit within Cemvita.

“I was drawn to Gold H2 because of its innovative mission to support the U.S. economy in this historical energy transition,” Sekhon says in a news release. “Over the last few years, my team [at NextEra] was heavily focused on the commercialization of clean hydrogen. When I came across Gold H2, it was clear that it was superior to each of its counterparts in both cost and [carbon intensity].”

Gold H2 explains that oil and gas companies have wrestled for decades with what to do with exhausted oil fields. With Gold H2’s first-of-its-kind biotechnology, these companies can find productive uses for oil wells by producing clean hydrogen at a low cost, the startup says.

“There is so much opportunity ahead of Gold H2 as the first company to use microbes in the subsurface to create a clean energy source,” Sekhon says. “Driving this dynamic industry change to empower clean hydrogen fuel production will be extremely rewarding.”

In 2022, Gold H2 celebrated its successful Permian Basin pilot and raised early-stage funding. In addition to Gold H2, Cemvita also spun out a resource mining operation called Endolith. In a podcast episode, Karimi discussed Cemvita's growth and spinout opportunities.

Rice University's student startup competition names 2024 winners, awards $100,000 in prizes

taking home the W

A group of Rice University student-founded companies shared $100,000 of cash prizes at an annual startup competition.

Liu Idea Lab for Innovation and Entrepreneurship's H. Albert Napier Rice Launch Challenge, hosted by Rice earlier this month, named its winners for 2024. HEXASpec, a company that's created a new material to improve heat management for the semiconductor industry, won the top prize and $50,000 cash.

Founded by Rice Ph.D. candidates Tianshu Zhai and Chen-Yang Lin, who are a part of Lilie’s 2024 Innovation Fellows program, HEXASpec is improving efficiency and sustainability within the semiconductor industry, which usually consumes millions of gallons of water used to cool data centers. According to Rice's news release, HEXASpec's "next-generation chip packaging offer 20 times higher thermal conductivity and improved protection performance, cooling the chips faster and reducing the operational surface temperature."

The rest of the winners included:

Second place and $25,000: CoFlux Purification
Third place and $15,000: Bonfire
Outstanding Achievement in Social Impact Award and $1,500: EmpowerU
Outstanding Achievement in Artificial Intelligence and $1,000: Sups and Levytation
Outstanding Achievement in Consumer Goods Prize and $1,000: The Blind Bag
Frank Liu Jr. Prize for Creative Innovations in Music, Fashion and the Arts and $1,500: Melody
Outstanding Achievement in Climate Solutions Prizes and $1,000: Solidec and HEXASpec
Outstanding Undergraduate Startup Award and $2,500: Women’s Wave
Audience Choice Award and $2,000: CoFlux Purification

The NRLC, open to Rice students, is Lilie's hallmark event. Last year's winner was fashion tech startup, Goldie.

“We are the home of everything entrepreneurship, innovation and research commercialization for the entire Rice student, faculty and alumni communities,” Kyle Judah, executive director at Lilie, says in a news release. “We’re a place for you to immerse yourself in a problem you care about, to experiment, to try and fail and keep trying and trying and trying again amongst a community of fellow rebels, coloring outside the lines of convention."

This year, the competition started with 100 student venture teams before being whittled down to the final five at the championship. The program is supported by Lilie’s mentor team, Frank Liu and the Liu Family Foundation, Rice Business, Rice’s Office of Innovation, and other donors

“The heart and soul of what we’re doing to really take it to the next level with entrepreneurship here at Rice is this fantastic team,” Peter Rodriguez, dean of Rice Business, adds. “And they’re doing an outstanding job every year, reaching further, bringing in more students. My understanding is we had more than 100 teams submit applications. It’s an extraordinarily high number. It tells you a lot about what we have at Rice and what this team has been cooking and making happen here at Rice for a long, long time.”

HEXASpec was founded by Rice Ph.D. candidates Tianshu Zhai and Chen-Yang Lin, who are a part of Lilie’s 2024 Innovation Fellows program. Photo courtesy of Rice

View All Listings

INNOVATIONMAP EMAILS ARE AWESOME